Last reviewed · How we verify
FF/UMEC/VI
FF/UMEC/VI is a triple combination inhaler that combines a long-acting beta-2 agonist, a long-acting muscarinic antagonist, and an inhaled corticosteroid to reduce airway inflammation and improve bronchodilation in chronic obstructive pulmonary disease.
FF/UMEC/VI is a triple combination inhaler that combines a long-acting beta-2 agonist, a long-acting muscarinic antagonist, and an inhaled corticosteroid to reduce airway inflammation and improve bronchodilation in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | FF/UMEC/VI |
|---|---|
| Also known as | Trelegy, TRELEGY ELLIPTA |
| Sponsor | Dr. Grace Parraga |
| Drug class | Triple combination inhaler (ICS/LAMA/LABA) |
| Target | Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone furoate (FF) is an inhaled corticosteroid that reduces airway inflammation. Umeclidinium (UMEC) is a long-acting muscarinic antagonist that provides bronchodilation by blocking acetylcholine receptors. Vilanterol (VI) is a long-acting beta-2 agonist that further enhances bronchodilation. Together, these three agents work synergistically to improve airflow and reduce COPD symptoms.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nasopharyngitis
Key clinical trials
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD (PHASE4)
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma (PHASE3)
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (PHASE4)
- Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma (PHASE3)
- Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |